Capital International Sarl Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Capital International Sarl increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 31.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 154,092 shares of the biopharmaceutical company's stock after buying an additional 37,067 shares during the period. Capital International Sarl's holdings in Bristol-Myers Squibb were worth $8,715,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. First Commonwealth Financial Corp PA bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $227,000. Demars Financial Group LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $49,866,000. MSH Capital Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $534,000. Zacks Investment Management grew its position in shares of Bristol-Myers Squibb by 4,936.4% in the 4th quarter. Zacks Investment Management now owns 250,965 shares of the biopharmaceutical company's stock valued at $14,195,000 after acquiring an additional 245,982 shares during the period. Finally, NewEdge Advisors LLC increased its position in Bristol-Myers Squibb by 5.0% during the fourth quarter. NewEdge Advisors LLC now owns 168,112 shares of the biopharmaceutical company's stock worth $9,508,000 after buying an additional 8,071 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Down 4.4 %

BMY traded down $2.18 during mid-day trading on Wednesday, reaching $47.64. 11,835,149 shares of the stock were exchanged, compared to its average volume of 12,997,744. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a 50 day moving average price of $56.71 and a two-hundred day moving average price of $56.59. The stock has a market capitalization of $96.94 billion, a PE ratio of -10.78, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.21%. Bristol-Myers Squibb's payout ratio is currently -56.11%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of research analyst reports. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Wells Fargo & Company upped their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Jefferies Financial Group lowered their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, Citigroup upped their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.